LAUSR

Patients with chronic hepatitis B (CHB) are at an increased risk of disease progression. The influence of hepatic steatosis (HS) to liver fibrosis was controversial. We aim to investigate the association between HS and liver fibrosis and explore the predicting factors for advanced fibrosis. CHB patients undergoing liver biopsy with complete assessments of HS, necroinflammation grade [histological activity index (HAI) score], and fibrosis stage were retrospectively recruited. Logistic regression analysis was performed to determine the factors associated with advanced liver fibrosis. In this cohort of 672 patients, 342 (50.9%) had HS and 267 (39.4%) were of advanced liver fibrosis. Age [odds ratio (OR) 1.026, 95% confidence interval (CI) 1.007–1.046, p = 0.008], body mass index (BMI, OR 1.091, 95% CI 1.026–1.159, p = 0.005), genotype (C vs. B) (OR 2.790, 95% CI 1.847–4.214, p < 0.001), platelet (OR 0.986, 95% CI 0.982–0.991, p < 0.001), and HAI score (OR 1.197, 95% CI 1.114–1.285, p < 0.001) were independent factors for advanced liver fibrosis in multivariate logistic regression analysis. HAI score was also a significantly associated factor for significant liver fibrosis in non-cirrhotic subpopulation (OR 1.578, 95% CI 1.375–1.810, p < 0.001). HS was not related to advanced/significant liver fibrosis in overall/non-cirrhotic population (p > 0.05). Significant or advanced liver fibrosis is associated with grade of necroinflammation but not with HS in CHB patients.